FDA Direct: Removing Black Box Warnings for HRT (Part 1/2)
Learn more about why the FDA is initiating label changes for hormone replacement therapy products for menopausal women.
▶︎
FDA Direct: Removing Black Box Warnings for HRT (Part 2/2)
▶︎
Ebola Survivor - Dr. Ian Crozier
▶︎
FDA Direct - Special Edition of FDA Direct
▶︎
Understanding the Nutrition Facts Label, the Updated “Healthy” Claim, and Other Nutrition Claims
▶︎
FDA Direct: To Boost or Not to Boost - Gathering New Evidence on Covid Boosters
▶︎
FDA Expert Panel on Menopause and Hormone Replacement Therapy for Women
▶︎
FDA Direct: Catching Up on Agency Reforms
▶︎
CDER & CBER All Hands: Implementing the FDA's Plausible Mechanism Framework
▶︎
FDA Direct: What's the Deal with Talc? - Recapping
▶︎
FDA Direct: Who Buys the Spin — Hook, Line and Sinker?
▶︎
FDA Direct: From Menopause to Food Safety: FDA's Latest Regulatory Priorities
▶︎
FDA Expert Panel on Testosterone Replacement Therapy for Men
▶︎
FDA Direct: Combating Rare Diseases at the FDA
▶︎
Advancing Real-Time Clinical Trials
▶︎
FDA Direct: No One Think It's a Good Idea for Kids to Consume Petroleum Products
▶︎
FDA Grand Rounds - Clinical Omics Biomarker Discovery and Validation in Precision Medicine
▶︎
FDA Direct, Striking a Balance - Framework for Future Covid-19 Vaccine Decisions
▶︎
Commissioner’s National Priority Voucher (CNPV) Pilot Program Public Hearing
▶︎
CDER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products
▶︎